In terms of revenue, the Global Digital PCR (dPCR) and Real-time PCR (qPCR) Market is expected to reach 8,860.22 USD Million by 2028, growing at a CAGR of 8.80% from 2022 to 2028.

Increasing incidence & prevalence of genetic & infectious diseases; technological advancement in PCR; and rising number of CRO, forensic, and other research laboratories are driving the growth in dPCR and qPCR market. Moreover, emerging opportunities from Asian countries and transition from plant to genome based drug discovery will provide high opportunities for this market in forecast period. On the other hand, technical limitations associated with PCR and high cost of PCR devices are expected to restrict the growth of this market.

Key Findings:

• The hospitals and diagnostic sub-segment is anticipated to dominate the end-user segment for Digital PCR (dPCR) and Real-time PCR (qPCR) Market. The rise in this segment is owing to qPCR reagents in clinical diagnostic applications and ongoing expansion of healthcare infrastructure across emerging countries.
• Clinical application segment is accounted for the largest market share in 2021. Device sensitivity, better precision, and absolute quantification of target molecule are the key reasons for this segment to flourish.
• North America is the largest regional segment. This surge is attributed to the rising demand of digital PCR & real-time PCR in develop economies such as U.S. and Canada.

Some of key players in Digital PCR (dPCR) and Real-time PCR (qPCR) Market include, Thermo Fisher Scientific (US), Bio-Rad Laboratories Inc. (US), and F. Hoffmann-La Roche, Ltd. (Switzerland), Abbott Laboratories (US), Agilent Technologies (US), Analytik Jena AG (Switzerland), Becton Dikinson and Company (US), bioMérieux SA (France), Danaher Corporation (US), Eppendorf (Germany), Fluidigm Corporation (US), Merck KGaA  (Germany), QIAGEN N.V.  (Netherlands), Takara Bio (Japan), Meridian Bioscience (US), Promega Corporation (US), Enzo Life Sciences, Inc. (US), Bioneer (South Korea), ELITech Group (France), and Quidel Corporation (US)..

More than 20 billion people worldwide have been infected with hepatitis B virus (HBV), and HBV is a common cause of liver diseases and liver cancers. The fatality of these diseases as well as their relation to hepatitis infection is well-established; 600,000 HBV-related deaths are estimated to occur every year and 73% of liver cancer deaths worldwide are due to hepatitis viruses, with a higher prevalence in developing countries.

North America is expected to dominate the global Digital PCR (dPCR) and Real-time PCR (qPCR) Market in 2021 and is likely to continue the same trend during the forecast period. Increase in government initiatives and support in healthcare industry is likely to generate demand in this region for this market in near future. Increase in R&D for developing new techniques in digital PCR and real time PCR in healthcare industry in countries such as U.S. & Canada are further adding spot light. Significant improvements in the clinical infrastructure, especially in the developing economies, are providing a thrust to the Digital PCR (dPCR) and Real-time PCR (qPCR) Market growth.